1. Home
  2. XP vs TECH Comparison

XP vs TECH Comparison

Compare XP & TECH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo XP Inc.

XP

XP Inc.

HOLD

Current Price

$17.61

Market Cap

10.1B

Sector

Finance

ML Signal

HOLD

Logo Bio-Techne Corp

TECH

Bio-Techne Corp

HOLD

Current Price

$58.50

Market Cap

9.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XP
TECH
Founded
2001
1976
Country
Cayman Islands
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.1B
9.5B
IPO Year
2019
1989

Fundamental Metrics

Financial Performance
Metric
XP
TECH
Price
$17.61
$58.50
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
14
Target Price
$22.40
$71.23
AVG Volume (30 Days)
8.8M
1.8M
Earning Date
11-17-2025
02-04-2026
Dividend Yield
1.03%
0.55%
EPS Growth
18.53
N/A
EPS
1.76
0.49
Revenue
$3,229,174,949.00
$1,216,732,000.00
Revenue This Year
$17.71
$2.33
Revenue Next Year
$13.05
$7.05
P/E Ratio
$9.92
$120.21
Revenue Growth
8.33
3.85
52 Week Low
$10.82
$46.01
52 Week High
$20.64
$79.28

Technical Indicators

Market Signals
Indicator
XP
TECH
Relative Strength Index (RSI) 43.89 42.18
Support Level $17.37 $58.75
Resistance Level $18.12 $61.20
Average True Range (ATR) 0.71 2.01
MACD -0.20 -0.54
Stochastic Oscillator 8.76 13.44

Price Performance

Historical Comparison
XP
TECH

About XP XP Inc.

XP Inc is a Cayman Island-based technology-driven financial services platform. It is a provider of low-fee financial products and services in Brazil. The company evaluates its business through a single segment such as monitoring operations, making decisions on fund allocation, and evaluating the performance. It generates revenue through the Brokerage commission.

About TECH Bio-Techne Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

Share on Social Networks: